Zevenbergen Capital Investments LLC Trims Stock Position in Natera, Inc. (NASDAQ:NTRA)

Zevenbergen Capital Investments LLC cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 440,211 shares of the medical research company's stock after selling 25,099 shares during the period. Natera accounts for approximately 1.4% of Zevenbergen Capital Investments LLC's holdings, making the stock its 23rd biggest holding. Zevenbergen Capital Investments LLC owned about 0.33% of Natera worth $69,685,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Cerity Partners LLC increased its stake in Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock worth $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Natera in the third quarter valued at $385,000. Everence Capital Management Inc. acquired a new position in shares of Natera during the 4th quarter worth about $573,000. Alpha DNA Investment Management LLC acquired a new position in Natera during the third quarter worth approximately $505,000. Finally, Smartleaf Asset Management LLC raised its stake in Natera by 50.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after acquiring an additional 220 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Stock Down 2.9 %

Shares of NASDAQ:NTRA traded down $4.36 on Friday, reaching $143.94. The company had a trading volume of 1,258,459 shares, compared to its average volume of 1,364,577. The firm has a market capitalization of $19.46 billion, a PE ratio of -81.78 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm's 50 day simple moving average is $159.60 and its 200-day simple moving average is $150.72. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. As a group, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the transaction, the chief executive officer now owns 267,629 shares of the company's stock, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John Fesko sold 663 shares of Natera stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 306,797 shares of company stock worth $48,940,883 over the last quarter. Insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NTRA. The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Piper Sandler lifted their target price on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Finally, Morgan Stanley boosted their price target on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and an average price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.